IOVA Iovance Biotherapeutics 8-K2021Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors January 2021 © 2021, Iovance Biotherapeutics, Inc 1
7 Jan 21
Files
SEC
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
IOVA 8-K Filings
- 7 Jan 21 Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors January 2021 © 2021, Iovance Biotherapeutics, Inc 1
- 14 Dec 20 Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
- 5 Nov 20 Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020
- 14 Oct 20 Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…